Pfizer reports positive phase III data on rheumatoid arthritis drug
19 April 2011 00:00 in Pharmaceutical Company Product News
Pfizer has announced positive clinical trial data from an ongoing study of tofacitinib, its investigational treatment for moderate-to-severe active rheumatoid arthritis.
The oral JAK inhibitor is currently involved in a two-year phase III trial called Oral Scan, which aims to compare the efficacy of the drug to placebo among patients who have proven unresponsive to treatment with methotrexate.
Analysis of the data collated after the first year of research showed that the 10mg dose of the drug delivered significant benefits in treating signs and symptoms of the disease, as well as reducing structural damage and improving physical function.
In addition, the data revealed no new safety signals, with overall performance data remaining consistent with previously collated clinical results.
Further information from this study will be presented by Pfizer at a future scientific conference, while two-year findings from the trial will be reported next year.
Last week, the company published positive data from a study of tafamidis, a developmental transthyretin familial amyloid polyneuropathy treatment.
Other news stories from 19/04/2011
Related news
Read more in the Zenopa News Archive
How this news is generated
Story collated for Zenopa by the Adfero News Agency
